Biomarker and Therapeutic Target Discovery in Gastrointestinal (GI) Cancers

This project focuses on the discovery of predictive biomarkers and therapeutic vulnerabilities in pancreatic, colorectal, and gastric cancers, building on our ongoing work in gastric and gastroesophageal junction cancers. Through multi-omic profiling, gene-expression analysis, and tumor microenvironment characterization, we aim to guide the selection of patients for upfront surgery, neoadjuvant chemotherapy, or immunotherapy. Special emphasis is placed on immunotherapy-responsive subgroups, including those defined by molecular, microenvironmental, or genomic features, with machine learning approaches aiding the development of clinically actionable risk models.